Use of non‐vitamin K antagonist oral anticoagulants in atrial fibrillation patients: insights from a specialist atrial fibrillation clinic

By  

INTERNATIONAL JOURNAL OF CLINICAL PRACTICE (ELECTRONIC), Vol. 69, Iss. 11, 2015-11 ,pp. : 1341-1348

John Wiley & Sons Inc

Access to resources Recommend Favorite

Characteristics of patients with non-valvular atrial fibrillation using dabigatran or warfarin in the US

By Schoof Nils   Schnee Janet   Schneider Gary   Gawlik Melissa   Zint Kristina   Clemens Andreas   Bartels Dorothee B.  

Current Medical Research and Opinion, Vol. 30, Iss. 5, 2014-05 ,pp. : 795-804

Informa Healthcare

Access to resources Recommend Favorite

Non‐vitamin K antagonist oral anticoagulants (NOACs) in patients with concomitant atrial fibrillation and heart failure: a systemic review and meta‐analysis of randomized trials

By  

EUROPEAN JOURNAL OF HEART FAILURE, Vol. 17, Iss. 11, 2015-11 ,pp. : 1192-1200

John Wiley & Sons Inc

Access to resources Recommend Favorite

Medical costs in the US of clinical events associated with oral anticoagulant (OAC) use compared to warfarin among non-valvular atrial fibrillation patients ≥75 and <75 years of age, based on the ARISTOTLE, RE-LY, and ROCKET-AF trials

By Deitelzweig Steve   Amin Alpesh   Jing Yonghua   Makenbaeva Dinara   Wiederkehr Daniel   Lin Jay   Graham John  

Journal of Medical Economics, Vol. 16, Iss. 9, 2013-09 ,pp. : 1163-1168

Informa Healthcare

Access to resources Recommend Favorite

Hospital length of stay: is rivaroxaban associated with shorter inpatient stay compared to warfarin among patients with non-valvular atrial fibrillation?

By Laliberté François   Pilon Dominic   Raut Monika K.   Nelson Winnie W.   Olson William H.   Germain Guillaume   Schein Jeff R.   Lefebvre Patrick  

Current Medical Research and Opinion, Vol. 30, Iss. 4, 2014-04 ,pp. : 645-653

Informa Healthcare

Access to resources Recommend Favorite